Observational Secondary Database Study to Assess the Long-Term Safety of Mirikizumab (I6T-MC-B004)

Study identification

• EU PAS number:
  EUPAS105671
• Study ID:
  105672
• Official title and acronym:
  Observational Secondary Database Study to Assess the Long-Term Safety of Mirikizumab (I6T-MC-B004)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Planned

Research institutions and networks

Institutions

Optum

Germany

Study timelines

Date when funding contract was signed

Actual: 17/05/2023

Study start date

Planned: 26/05/2025

Date of final study report

Planned: 31/12/2037

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)